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Background: Studies on the ‘self-medication hypothesis’ have focused on substance abuse as an attempt to
alleviate emotional suffering.
Methods: We have investigated concomitant substances of abuse in 150 bipolar heroin addicts clustered according
to their clinical presentation at treatment entry (depressive episode, hypomanic episode, manic episode and mixed
episode). Bipolar heroin addicted patients were chosen because they tend to have a concomitant poly-substance
abuse and because, as compared with patients suffering for other mental illnesses, they more clearly reveal a
variety of identifiable affective states.
Results: Patients with a depressive episode more frequently used non-prescribed anxiolytic-hypnotics. They were
found to use cocaine-amphetamines more frequently during a hypomanic episode, whereas the use of cannabis
and cocaine-amphetamines occurred more frequently during a manic episode. The associated use of alcohol,
cocaine-amphetamines and cannabinoids was more frequently encountered during a mixed episode. Limitations:
apart from the difficulty in determining whether the substance use modifies the mood or the mood state
determines the substance used, this is a report on a retrospective analysis, rather than a study specifically designed
to elucidate the issue; in addition, no information was available on the temperament of our subjects. Assessments
of the same subject in various clinical presentations would have provided a better level of information.
Conclusions: Besides one expected result – the prominent use of CNS stimulants during a depressive phase of
bipolar patients – this study supports the hypothesis that mood elation is a pleasurable, rewarding experience that,
in bipolar patients, can be started or prolonged by means of CNS stimulant drugs. Stimulant use was, therefore,
more prevalent during the ‘up’ rather than the ‘down’ phase of the illness.Background
Psychiatric disorders and substance abuse commonly co-
occur. Population-based studies have provided docu-
mentation that, of all patients with major psychiatric
disorders, those with bipolar disorder show the highest
prevalence of comorbid substance abuse and depend-
ence. The cause of this high comorbidity rate has not
been clearly established, and the relationship is probably
bidirectional [1]. One explanation for this co-occurrence
is the 'self-medication hypothesis', which states that* Correspondence: maremman@med.unipi.it
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It has been found that about 50% of individuals with
bipolar disorder have a lifetime history of substance
abuse or dependence [3]. Furthermore, bipolar I subjects
appear to have higher rates of these comorbid conditions
than bipolar II subjects [4].
Research has consistently shown that substance abuse
in bipolar patients may have negative consequences both
on clinical characteristics and long-term course: drug
addiction is associated with medication non-compliance
[5], a higher frequency of mixed or dysphoric mania
and, possibly, an earlier onset of affective symptoms
[6,7], more severe impairment of social functioning [8],
greater subjective distress and less resourcefulness in
coping [9], more hospitalizations and poorer prognosesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Maremmani et al. Annals of General Psychiatry 2012, 11:23 Page 2 of 7
http://www.annals-general-psychiatry.com/content/11/1/23[10,11], together with a higher frequency of suicide
attempts [12,13].
Alcohol and cannabis are the substances most often
abused, followed by cocaine and then opioids. In terms
of specificity, a link seems to exist between cocaine use,
as evaluated among poly-abusers of different categories,
and bipolar disorders [14-16]. When abusing cocaine,
bipolar patients showed significantly higher rates of
post-traumatic stress disorder and antisocial personality
disorder, and were more likely to present in a mixed
mood state [17].
Alcohol abuse and dependence show a lifetime preva-
lence 3–4 times higher in patients with bipolar disorders
than in the general population, while the lifetime preva-
lence of mood disorders in alcohol-dependent subjects is
approximately 10 times higher than in the general popu-
lation [18]. Most bipolar patients run the risk of devel-
oping lifetime drug or alcohol-related problems, which
may in their turn contribute to more varied and complex
clinical presentations, so increasing the risk of a depres-
sive episode in the near term [19], poorer lithium
response, functional disability and elevated suicide risk
[20], as well as high rates of suicide attempts [21,22].
Moreover, alcohol addiction may exacerbate impulsive
behaviours and risk-taking propensities in bipolar
patients [23].
With respect to cannabis use, some papers have
pointed out that marijuana is not only often abused by
patients suffering from bipolar disorder, but also induces
manic symptoms [24-27]. Additionally, cannabis-using
bipolar patients experienced less satisfaction with life,
had a lower probability of having a romantic relationship
compared with non-users [28,29], and also had more
severe alcohol and other drug use [30].
Regarding heroin use, very few studies have been con-
ducted on the specific effects of its abuse in the clinical
course of bipolar patients [16,31].
Studies on the self-medication hypothesis (SMH) have
focused on the use of heroin and cocaine dependence as
an attempt to alleviate emotional suffering [32]. Most
addicts do not choose drugs randomly to alleviate pain-
ful affective states and their underlying psychiatric disor-
ders. Rather, drugs are chosen because an individual
discovers a specific psychopharmacological action that
helps to alleviate an individual’s suffering. Recently,
greater emphasis has been placed on understanding
addiction as a form of ‘self-medication’ to alleviate suf-
fering, with less emphasis on its severe psychopathology.
As the ‘self-medication’ theory suggests, patients to
modulate their mood by decreasing their dysphoria may
use heroin. In other words, patients appear to select sub-
stances that they expect to have a ‘healing’ effect. In bi-
polar patients cocaine appears to exercise an appeal
because of its ability to relieve distress associated withdepression [32]. Recently Khantzian revised his theory
[33] and expanded the number of affective states to be
examined, including alexithymia, to better operationalize
SMH, but some authors indicated that affective mea-
sures did not have the expected relationship with
reported substance use [34,35]. In this study, to further
test the validity of Khantzian’s hypothesis, we compared
concomitant substances of abuse in bipolar heroin
addicts according to their clinical presentation (depres-
sive episode, hypomanic episode, manic episode and
mixed episode). Bipolar patients have been chosen be-
cause, as compared with patients suffering for other
mental illnesses, they are more likely to clearly show
various different identifiable affective states. We consid-
ered heroin-dependent bipolar patients as Khantzian
developed his hypothesis treating heroin addicts. More-
over, bipolar patients are generally multi-drug abusers.
The choice of these patients is also interesting for the
fact that heroin use in bipolar disorder is perhaps the
least understood and researched groups of patients with
bipolar disorder and substance use.
Khantzian’s hypothesis would be supported if the use
of CNS stimulants were prominent in the depressive
phase and CNS depressants in hypomanic or manic
phases, at least when patients complain of altered mood
or insufficient balance of affective symptoms despite
putative self-medication by substance use.
Methods
Design of the study
This is a retrospective, observational, case–control study.
The research study was implemented using a dataset
from previous studies on MMTP carried out in Italy and
used in previous published articles (Pisa addiction dataset:
a database including anonymous individual information
originally collected for clinical and research purposes).
The study included patients treated at Santa Chiara
University Hospital, Department of Psychiatry, Univer-
sity of Pisa, Italy during the period 1994–2010. All
patients gave their informed consent to the anonymous
use of their personal data records for research purposes.
Sample
Patients included in the Pisa addiction dataset were
selected on the basis of the following characteristics:
 Diagnosis of Bipolar I or II disorders according to
DSM-IV TR and various DSM criteria
 Diagnosis of opioid dependence with physical
dependence according to DSM-IV TR and various
DSM criteria
 Being at their lifetime first hospitalization
 Not receiving medication for the treatment of
bipolar disorders
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We excluded patients:
 Receiving opioid agonist medications for opioid
dependence
 Using illegal methadone
Patients using opioid agonist medications or illegally
obtained methadone were excluded to limit the confus-
ing effects of this medication on clinical psychiatric pres-
entation [36].
We included in the study 150 consecutive bipolar her-
oin addicts. The mean age of these patients was
29 ± 6 years old (range 17–50). Ninety-one (60.7%) were
male; 85 (56.7%) were single, 104 (69.3%) had less than
9 years of education, and 70 (46.7%) were unemployed.
As to drug addiction history, 127 (84.7%) patients
reported physical complications. 100 (66.7%) were un-
employed, 92 (61.3%) showed household, 53 (35.3%) ro-
mantic, 81 (54.0%) social leisure and 72 (48.0%) legal
difficulties. 86 (57.3%) were poly-abusers (3 or more
substances), 120 (80.0%) had experienced past treat-
ment failures.
In order to obtain groups of patients differing in clin-
ical presentation at hospitalization, patients were divided
into four groups on the basis of their episode polarity.
103 patients (68.6%) showed a major depressive episode;
22 (14.7%) a hypomanic episode; 5 (3.3%), a full manic
episode and 20 (13.3%) a mixed episode, according
DSM-IV TR and various DSM criteria.Instruments
Drug addiction history questionnaire (DAH-Q)
Addiction-related information was collected by means of
DAH-Q [37] administered by a psychiatrist. The DAH-
Q is a multi-scale questionnaire that comprises the fol-
lowing categories: demographic data, physical health
(hepatic, vascular and lymphatic pathology, gastroin-
testinal disorders, sexual disorders, dental pathology,
HIV seropositivity), mental health (awareness of illness,
memory disorders, anxiety disorders, mood disorders,
aggression, thought disorders, sensory perception disor-
ders), substance abuse (use of alcohol, opiates, CNS
depressants, CNS stimulants, hallucinogens, phencyclid-
ine, cannabis, inhalants, poly-substance abuse), social ad-
justment and environmental factors (employment family,
sex, socialization and leisure time, legal problems), clin-
ical characteristics as frequency of drug use, patterns of
use, phase, nosology, treatment history (previous and
current treatments). Items are set up so as to elicit
dichotomous answers (yes/no).Substance Use
Regarding toxicological urinalyses, we utilized the rou-
tine analyses as used for all hospitalized patients. The
enzyme-multiplied immunotechniques for opiates,
methadone, benzodiazepines, hypnotics, cocaine, amphe-
tamines, hallucinogens, cannabinoids and inhalants were
used. Problematic alcohol use was defined according to
a lifetime history of frequent intoxication and/or nega-
tive consequences of habitual use on their social adjust-
ment (work, family, social/leisure or legal issues).
Data analysis
The 4 groups clustered according to the clinical presen-
tation at hospitalization were compared for demo-
graphic, DAH-Q factors and concomitant substance
abuse by means of the chi-square test for categorical
variables (with contrasts), and one-way analysis of vari-
ance for continuous variables, a posteriori contrasts
according to the Scheffe’s procedure.
All analyses were carried out using the statistical pack-
age of SPSS (version 20.0). Since this is an exploratory
study, statistical tests were considered significant at the
p <0.05 level.
Results
Table 1 shows the demographic and clinical characteris-
tics of our patients according to their present episode
polarity. No statistically significant differences among
the four groups were observed as regards age, sex, edu-
cational level, marital status, job and financial need.
Nor were any statistically significant differences
observed either among the majority of DAH-RS factors
(somatic comorbidity, altered mental status, work, fam-
ily, romantic involvement, social leisure and legal pro-
blems, poly-abusers, associated treatments).
Table 2 shows differences regarding concomitant sub-
stance abuse between the four groups of patients.
No statistically significant differences were observed
regarding the abuse of heroin.
Patients with a depressive episode at clinical presenta-
tions showed more frequent use of unprescribed anxio-
lytic-hypnotics. During a hypomanic episode, patients
more frequently used cocaine-amphetamines, while, dur-
ing a manic episode, patients more frequently used can-
nabis and cocaine-amphetamines. The associated use of
alcohol, cocaine-amphetamines and cannabinoids was
more frequently encountered during a mixed episode.
Discussion
As we observed in our sample, patients take anxiolytic-
hypnotics, which belong to the class of central nervous
system (CNS) depressants, with greater frequency dur-
ing a depressive episode. They take CNS stimulants










N (%) N (%) N (%) N (%)
Age (M± sd) 28.81 ± 6.4 28.77 ± 4.7 26.80 ± 5.6 28.45 ± 5.1 0.69 0.55
Gender (males) 63 (61.2) 13 (59.1) 3 (60.0) 12 (60.0) 0.03 0.99
Low Education Level (≤8 yrs) 71 (68.9) 16 (72.7) 4 (80.0) 13 (65.0) 0.57 0.90
Marital status (single) 62 (60.2) 11 (50.0) 3 (60.0) 9 (45.0) 2.05 0.56
Unemployed 48 (46.6) 11 (50.0) 3 (60.0) 8 (40.0) 6.20 0.71
Financial need 20 (19.6) 4 (18.2) 0 (0.0) 7 (35.0) 3.93 0.26
DAH-Q factors
1. Somatic comorbidity 87 (84.5) 17 (77.3) 4 (80.0) 19 (95.0) 2.65 0.44
2. Altered mental status 103 (100) 22 (100) 5 (100) 20 (100) - -
3. Work, major problems 73 (70.9) 13 (59.1) 3 (60.0) 11 (55.0) 2.71 0.43
4. Family, major problems 69 (67.0) 10 (45.5) 2 (40.0) 11 (55.0) 5.02 0.16
5. Romantic involvement, major problems 37 (35.9) 8 (36.4) 1 (20.0) 7 (35.0) 0.54 0.90
6. Social leisure, major problems 60 (58.3) 11 (50.0) 2 (40.0) 8 (40.0) 2.86 0.41
7. Legal problems 53 (51.5) 10 (45.5) 2 (40.0) 7 (35.0) 2.03 0.56
8. Poly-abusers 56 (54.4) 12 (54.5) 4 (80.0) 14 (70.0) 2.80 0.42
9. Past opioid agonist treatment failure(s) 86 (83.5)a 19 (86.9)a 4 (80.0)a 11 (55.0)b 9.15 0.02
10. Associated treatment needed 103 (100) 22 (100) 5 (100) 20 (100) - -
Each (a,b) letter indicates a subset of categories “present episode polarity” which portions of the column are not very different at level .05.
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hypomanic episode, whereas they tend to take both CNS
stimulants and cannabinoids with a greater frequency
during a manic episode; lastly, during a mixed episode
they take CNS depressants (alcohol), stimulants, and
hallucinogens together.
In the case of depressed patients, the use of CNS
depressants is consistent with their toxicological status.
It should be noted that benzodiazepine use in heroin
addicts could be correlated with a condition of opiate
dependence improperly compensated by street heroin
[38]. From a psychopathological standpoint, depressants
may aggravate the slowing of cognitive and physical
functions caused by depression, but it remains true that
these medications are effective in treating insomnia and
anxiety, which are often symptoms of depression. Also,
patients may not be seeking an actual ‘lift’ of their





N (%) N (%)
Alcohol 50 (48.5)b 8 (38.1)
Anxiolytics and/or Hypnotics 72 (70.6)a 10 (45.5)
Cocaine-amphetamines 19 (18.6)b 16 (72.7)
Cannabinoids 40 (39.6)b 9 (40.9)
Each (a,b) letter indicates a subset of categories “present episode polarity” which powhich the pain of depression is cancelled. In depression,
what is seen is not a higher use of stimulant substances,
but the use of CNS Depressants that may sometimes
relieve some aspects of depression (or may not do so) –
a situation that fails to provide support to Khantzian’s
hypothesis.
More clearly, Khantzian’s hypothesis does not seem to
be supported by the other three kinds of clinical presen-
tations. Patients during a hypomanic, manic or mixed
episode, despite experiencing a state of excitement, tend
to continue their abuse of psychostimulants, further
reinforcing and elevating their mental state. This is
consistent with a proposed bipolar-stimulant spectrum
where subthreshold bipolar traits are aggravated by
stimulant abuse [39].
If we focus on heroin-dependent subjects, the con-
comitant use of cocaine is reported to be a relevant








N (%) N (%)
b 1 (20.0)b 15 (75.0)a 0.23 0.044
b 2 (40.0)b 5 (25.0)b 0.34 0.000
a 5 (100.0)a 13 (65.0)a 0.53 0.000
b 4 (80.0)a 15 (75.0)a 0.27 0.011
rtions of the column are not very different at level .05.
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heroin-cocaine abusers have been compared, a direct
relationship has been found between cocaine abuse and
the rate of psychiatric disorders, together with correl-
ation with the severity of self-rated psychopathology
[40]. We do not know if this lack of awareness of
psychopathological symptoms is due to the use of
cocaine or to the underlying excitement that sustains
cocaine use. Moreover, if cocaine use represents self-
enhancement of one's level of hypomania, cyclothymia
or hyperthymia, the craving for hypomania is likely to be
particularly strong in heroin addicts, whose level of
excitement is lowered by heroin use [15]. In addition,
cocaine has been reported to induce a higher frequency
of mixed states when abused by bipolar patients [17].
This evidence suggests that some bipolar patients,
after deciding to use cocaine instead of being excited,
may have shifted from a manic or hypomanic to a
mixed episode.
During a manic episode, patients show a high level
of consumption of stimulants and cannabinoids. In the
literature, the abuse of cannabinoids in bipolar patients
has been found to induce manic symptoms [24], so it is
possible that, in our manic patients, as with cocaine use,
they may use cannabinoids to optimize their level of
excitement. To date, cannabis use is also considered to
be one of the most important risk factors for schizophre-
nia, thanks to its ability to precipitate or exacerbate
psychotic symptoms [41-46]. In line with this assump-
tion, in our sample, cannabis is mainly abused in manic
and mixed states that, unlike depressive and hypomanic
episodes, are often characterized by the presence of
psychotic symptoms. Whatever the causes of the use of
cannabis, Khantzian’s hypothesis is not supported in its
application to cannabis use. For many subjects, ending
cannabis use is difficult to achieve, not only because
of prior habits of use, but also because of the attend-
ant psychotic symptoms, including poor insight and
judgment, lack of impulse control and cognitive impair-
ment. Most of these subjects are unable to understand
that cannabis use is connected with the onset of symp-
toms [47].
One widely debated issue is whether Khantzian’s
hypothesis is a suitable instrument for interpreting
alcohol dependence. In examining patients with a mixed
episode, we found that, besides their abuse of cocaine-
amphetamines and cannabinoids, and in contrast with
the other three clinical presentation groups, they often
resort to alcohol use. Patients experience their mixed
mood as something undesirable and unpleasant, but
they still continue to consume substances that tend to
preserve their mixed, dysphoric state. Craving for sub-
stances and dependence create a loop, a senseless vicious
circle in which patients obtain neither satisfaction (moodelation) nor physical benefit (relief ). In line with this
observation, a past or current alcohol use disorder has
proved to raise the likelihood of a switch from depres-
sive to manic, mixed or hypomanic states in patients
with bipolar disorder [48]. Nervousness in alcoholic
patients has been hypothesized to be the only negative
mood state to predict increases in alcohol consumption
later in the course of the day. Further examination of
this within-person relationship has demonstrated that
men were more likely to consume alcohol when nervous
than were women, but this association is unrelated to
family history of alcoholism, problem drinking patterns,
or traits of anxiety and depression. Consistently with the
self-medication hypothesis, alcohol consumption has
been associated with lower levels of nervousness, but
this effect varies in a way dependent on several demo-
graphic and clinical variables [49]. Almost one quarter
of individuals with mood disorders use alcohol or drugs
to relieve symptoms, with the highest prevalence of self-
medication in bipolar I disorder. After checking the
effects of substance use disorders, self-medication has
been associated with higher rates of comorbid anxiety
and personality disorders than those found in individuals
who do not self-medicate [50]. On the basis of these
data we believe that, in the case of alcohol, Khantzian’s
hypothesis accounts for anxiety disorders more satisfac-
torily than mood disorders, although it must be added
that it actually explains controlled rather than addictive
use. In fact, enduring use, despite the worsening, or the
inadequate balance, of symptoms, is inconsistent with
a current self-medicating explanation, although that
explanation may have been appropriate in a previous
stage of controlled use. It should also be remembered
that patients were assessed for mood during current
drug use, thus ruling out the ambiguity between spon-
taneous mood swings and substance-induced intoxica-
tion. In fact, our patients had been displaying affective
dysregulation for some time before being diagnosed, and
had been engaged in substance use, which was bound
to worsen the affective core of their clinical pictures (i.e.
stimulants during excitement and depressants during
depression). The hypothesis of symptomatological over-
lap between temporary substance-related intoxication
and mood states is superseded in this way.
After reviewing our data we speculate that, setting
aside depressive and mixed episodes, the abuse of sub-
stances in hypomanic and manic episodes of bipolar
disorder is more probably due to patients’ desire to
maintain their current affective state rather than to
resolve depressed mood.
These considerations also provide a possible explan-
ation for the fact that bipolar patients tend not to
comply with therapy during hypomanic, manic and
mixed states [51-53]. In the literature, patients’ lack of
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associated with their lack of insight into their mental ill-
ness [54-56]. We go beyond that in suggesting that,
during hypomanic and manic phases, bipolar patients
do not comply with prescribed therapies and tend to
exacerbate their mental status by means of substances,
not only because they are unaware of their mental ill-
ness, but also because they somehow live the current
episode as a pleasurable and rewarding experience (in
cases of addiction to mania).
The obvious limitations of this study are due to the
fact that this is a retrospective analysis carried out on a
small cohort of patients, rather than a study specifically
designed to elucidate this issue. Assessments of the same
subject in various different clinical presentations of
the natural history of this illness would have provided a
better level of information. In addition we must consider
the difficulty in determining whether the substance
use modifies the mood or the mood state determines
the substance used. It is possible that stimulants are
seen in those with mania or hypomania because the
stimulant produced the mood state. They could have
been depressed without it. Lastly, we have no informa-
tion about the temperament of our subjects. So we
cannot exclude the presence of a depressive tempera-
ment that is able to moderate the nature of patients’
substance abuse; that would set up the need to modify
our hypothesis. One of our earlier findings, however,
was that heroin users mainly have a cyclothymic tem-
perament [57].
Conclusions
In summary, our data do not support Khantzian’s
hypothesis, if we exclude the use of CNS depressants
during a depressive phase to alleviate anxiety. Also in
this case, it can be said that CNS depressants are able to
alleviate insomnia and anxiety, but, more generally, may
aggravate the slowing of cognitive and physical functions
caused by depression. Khantzian’s hypothesis, more evi-
dently, does not seem to be able to account for the use
of psychostimulants and cannabis during a hypomanic,
manic or mixed state. In fact, the use of these substances
definitely leads to the further destabilization of mood.
On alcohol use we have to say that alcohol use, in our
subjects, is concomitant with a mixed state. Conversely,
we would have expected the use of alcohol during hypo-
manic and manic states to limit the euphoric condition.
Lastly, apart from the expected result of a prominent
use of CNS stimulants during a depressive phase of
bipolar patients, in line with Khantzian’s hypothesis, this
study showed that they were used more prominently
during hypomanic or manic phases. This apparently sup-
ports an alternative hypothesis – that mood elation is a
pleasurable and rewarding experience that, in bipolarpatients, can be started or prolonged by the use of CNS
stimulant drugs.
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